Suppr超能文献

相似文献

1
A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.
Haematologica. 2011 May;96(5):738-43. doi: 10.3324/haematol.2010.029868. Epub 2011 Jan 27.
2
Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A.
Haemophilia. 2016 Sep;22(5):e375-82. doi: 10.1111/hae.13019. Epub 2016 Jun 28.
3
Prophylaxis for severe haemophilia: clinical and economical issues.
Haemophilia. 2003 Jul;9(4):376-81. doi: 10.1046/j.1365-2516.2003.00764.x.
4
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Cochrane Database Syst Rev. 2006 Apr 19(2):CD003429. doi: 10.1002/14651858.CD003429.pub3.
5
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Cochrane Database Syst Rev. 2005 Apr 18(2):CD003429. doi: 10.1002/14651858.CD003429.pub2.
6
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Cochrane Database Syst Rev. 2011 Sep 7(9):CD003429. doi: 10.1002/14651858.CD003429.pub4.
9
Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
Haemophilia. 2009 Nov;15(6):1215-8. doi: 10.1111/j.1365-2516.2009.02079.x. Epub 2009 Aug 4.
10
Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
Haemophilia. 2016 May;22(3):374-80. doi: 10.1111/hae.12859. Epub 2015 Nov 19.

引用本文的文献

1
Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom.
Blood Adv. 2025 Mar 25;9(6):1312-1319. doi: 10.1182/bloodadvances.2024014376.
2
Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.
Appl Health Econ Health Policy. 2025 May;23(3):467-478. doi: 10.1007/s40258-024-00932-x. Epub 2024 Dec 2.
6
Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment.
Biotechnol Biotechnol Equip. 2014 May 4;28(3):576-582. doi: 10.1080/13102818.2014.926687. Epub 2014 Aug 26.
7
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.
Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):267-83. doi: 10.1586/14737167.2015.1001372. Epub 2015 Jan 14.
8
Prophylaxis for adults with haemophilia: one size does not fit all.
Blood Transfus. 2012 Apr;10(2):169-73. doi: 10.2450/2012.0174-11.

本文引用的文献

1
Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A.
Haemophilia. 2009 Jul;15(4):881-7. doi: 10.1111/j.1365-2516.2009.02019.x. Epub 2009 Apr 7.
3
Less severe bleeding in hemophilia B than in hemophilia A.
J Thromb Haemost. 2008 Nov;6(11):1982-3. doi: 10.1111/j.1538-7836.2008.03126.x. Epub 2008 Aug 22.
5
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
N Engl J Med. 2007 Aug 9;357(6):535-44. doi: 10.1056/NEJMoa067659.
6
RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia.
Haemophilia. 2007 Jul;13(4):345-50. doi: 10.1111/j.1365-2516.2007.01521.x.
7
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study.
J Thromb Haemost. 2006 Mar;4(3):510-6. doi: 10.1111/j.1538-7836.2006.01808.x.
8
Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters.
Haemophilia. 2005 Jan;11(1):43-8. doi: 10.1111/j.1365-2516.2005.01065.x.
10
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.
Haemophilia. 2002 Nov;8(6):753-60. doi: 10.1046/j.1365-2516.2002.00694.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验